## Daniel Krappmann

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1264113/daniel-krappmann-publications-by-year.pdf

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104<br/>papers9,188<br/>citations48<br/>h-index95<br/>g-index111<br/>ext. papers10,136<br/>ext. citations9<br/>avg, IF5.55<br/>L-index

#	Paper	IF	Citations
104	Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency Journal of Clinical Immunology, <b>2022</b> , 1	5.7	1
103	A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF- <b>B</b> signaling in activated T cells <i>Cellular and Molecular Life Sciences</i> , <b>2022</b> , 79, 112	10.3	1
102	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells <i>Science Signaling</i> , <b>2022</b> , 15, eabk3083	8.8	
101	TRAF6 prevents fatal inflammation by homeostatic suppression of MALT1 protease. <i>Science Immunology</i> , <b>2021</b> , 6, eabh2095	28	4
100	MALT1 is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-low, Triple-Negative Breast Cancer. <i>Molecular Cancer Research</i> , <b>2021</b> ,	6.6	3
99	A patent review of MALT1 inhibitors (2013-present). <i>Expert Opinion on Therapeutic Patents</i> , <b>2021</b> , 31, 1079-1096	6.8	1
98	Human immune disorder associated with homozygous hypomorphic mutation affecting MALT1B splice variant. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 775-778.e8	11.5	4
97	Methods to Study CARD11-BCL10-MALT1 Dependent Canonical NF- <b>B</b> Activation in Jurkat T Cells. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2366, 125-143	1.4	1
96	Use of Non-Natural Amino Acids for the Design and Synthesis of a Selective, Cell-Permeable MALT1 Activity-Based Probe. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 3996-4004	8.3	5
95	Classification and Nomenclature of Metacaspases and Paracaspases: No More Confusion with Caspases. <i>Molecular Cell</i> , <b>2020</b> , 77, 927-929	17.6	35
94	Regulation of the endosomal SNX27-retromer by OTULIN. <i>Nature Communications</i> , <b>2019</b> , 10, 4320	17.4	24
93	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma. <i>Journal of Pathology</i> , <b>2019</b> , 248, 142-154	9.4	5
92	Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. <i>Nature Communications</i> , <b>2019</b> , 10, 2352	17.4	38
91	Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation. <i>Nature Communications</i> , <b>2019</b> , 10, 701	17.4	34
90	MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells. <i>Cell Reports</i> , <b>2019</b> , 29, 873-888.e10	10.6	17
89	GSK3Imodulates NF- <b>B</b> activation and RelB degradation through site-specific phosphorylation of BCL10. <i>Scientific Reports</i> , <b>2018</b> , 8, 1352	4.9	10
88	S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells. <i>Leukemia</i> , <b>2018</b> , 32, 214-223	10.7	19

## (2016-2018)

87	Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 13191-13203	5.4	36
86	BCL10 - Bridging CARDs to Immune Activation. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1539	8.4	28
85	BCL10-CARD11 Fusion Mimics an Active CARD11 Seed That Triggers Constitutive BCL10 Oligomerization and Lymphocyte Activation. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2695	8.4	7
84	Molecular architecture and regulation of BCL10-MALT1 filaments. <i>Nature Communications</i> , <b>2018</b> , 9, 404	117.4	27
83	MALT1 activation by TRAF6 needs neither BCL10 nor CARD11. <i>Biochemical and Biophysical Research Communications</i> , <b>2018</b> , 506, 48-52	3.4	10
82	Immunoproteasome subunit deficiency has no influence on the canonical pathway of NF- <b>B</b> activation. <i>Molecular Immunology</i> , <b>2017</b> , 83, 147-153	4.3	24
81	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. <i>Blood</i> , <b>2017</b> , 129, 333-346	2.2	36
80	A Linear Diubiquitin-Based Probe for Efficient and Selective Detection of the Deubiquitinating Enzyme OTULIN. <i>Cell Chemical Biology</i> , <b>2017</b> , 24, 1299-1313.e7	8.2	22
79	Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma. <i>Leukemia</i> , <b>2017</b> , 31, 602-613	10.7	9
78	YOD1/TRAF6 association balances p62-dependent IL-1 signaling to NF- <b>B</b> . <i>ELife</i> , <b>2017</b> , 6,	8.9	29
77	Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells. <i>Nature Communications</i> , <b>2016</b> , 7, 11292	17.4	63
76	Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF- <b>B</b> activation. <i>Biochemical Journal</i> , <b>2016</b> , 473, 1759-68	3.8	37
75	Mechanisms of NF-B deregulation in lymphoid malignancies. Seminars in Cancer Biology, 2016, 39, 3-14	12.7	16
74	Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome. <i>ACS Medicinal Chemistry Letters</i> , <b>2016</b> , 7, 250-5	4.3	9
73	Development of new Malt1 inhibitors and probes. <i>Bioorganic and Medicinal Chemistry</i> , <b>2016</b> , 24, 3312-2	93.4	14
72	B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 611-611	2.2	
71	Canonical NF- <b>B</b> signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response. <i>Hepatology</i> , <b>2016</b> , 63, 1592-607	11.2	37
70	Inhibition of Canonical NF- <b>B</b> Signaling by a Small Molecule Targeting NEMO-Ubiquitin Interaction. <i>Scientific Reports</i> , <b>2016</b> , 6, 18934	4.9	22

69	Oncogenic CARMA1 couples NF- <b>B</b> and Ecatenin signaling in diffuse large B-cell lymphomas. <i>Oncogene</i> , <b>2016</b> , 35, 4269-81	9.2	31
68	Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. <i>Biological Chemistry</i> , <b>2016</b> , 397, 1315-1333	4.5	38
67	In vitro detection of NEMO-ubiquitin binding using DELFIA and microscale thermophoresis assays. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1280, 311-20	1.4	1
66	Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas. <i>Chemistry and Biology</i> , <b>2015</b> , 22, 129-38		30
65	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 42232-42	3.3	20
64	Detection of recombinant and cellular MALT1 paracaspase activity. <i>Methods in Molecular Biology</i> , <b>2015</b> , 1280, 239-46	1.4	2
63	Mechanisms and consequences of constitutive NF- <b>B</b> activation in B-cell lymphoid malignancies. <i>Oncogene</i> , <b>2014</b> , 33, 5655-65	9.2	82
62	Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation. <i>Nature Immunology</i> , <b>2014</b> , 15, 1079-89	19.1	184
61	MALT1 protease: equilibrating immunity versus tolerance. <i>EMBO Journal</i> , <b>2014</b> , 33, 2740-2	13	6
60	AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF- <b>B</b> signaling upon T cell activation. <i>Cell Communication and Signaling</i> , <b>2014</b> , 12, 49	7.5	15
59	Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. <i>Journal of Neuroinflammation</i> , <b>2014</b> , 11, 124	10.1	55
58	Structural analysis of phenothiazine derivatives as allosteric inhibitors of the MALT1 paracaspase. <i>Angewandte Chemie - International Edition</i> , <b>2013</b> , 52, 10384-7	16.4	56
57	Progressive stages of mitochondrial destruction caused by cell toxic bile salts. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , <b>2013</b> , 1828, 2121-33	3.8	53
56	The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO. <i>Molecular Cell</i> , <b>2013</b> , 49, 908-21	17.6	152
55	OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. <i>Cell</i> , <b>2013</b> , 153, 1312-26	56.2	304
54	Shaping oncogenic NF- <b>B</b> activity in the nucleus. <i>Blood</i> , <b>2013</b> , 122, 2146-7	2.2	4
53	MALT1 paracaspase: a unique protease involved in B-cell lymphomagenesis. <i>International Journal of Hematologic Oncology</i> , <b>2013</b> , 2, 409-417	1	2
52	Strukturelle Analyse von Phenothiazin-Derivaten als allosterische Inhibitoren der MALT1-Paracaspase. <i>Angewandte Chemie</i> , <b>2013</b> , 125, 10575-10579	3.6	

51	Measurement of Endogenous MALT1 Activity. <i>Bio-protocol</i> , <b>2013</b> , 3,	0.9	1
50	Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. <i>Cancer Cell</i> , <b>2012</b> , 22, 825-37	24.3	176
49	A20 and CYLD do not share significant overlapping functions during B cell development and activation. <i>Journal of Immunology</i> , <b>2012</b> , 189, 4437-43	5.3	21
48	Dlg3 trafficking and apical tight junction formation is regulated by nedd4 and nedd4-2 e3[libiquitin ligases. <i>Developmental Cell</i> , <b>2011</b> , 21, 479-91	10.2	42
47	Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation. <i>EMBO Journal</i> , <b>2011</b> , 30, 594-605	13	51
46	NF- <b>B</b> essential modulator (NEMO) interaction with linear and lys-63 ubiquitin chains contributes to NF- <b>B</b> activation. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 26107-17	5.4	84
45	The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 7522-34	5.4	77
44	Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 272-7	11.5	112
43	Signals from the nucleus: activation of NF-kappaB by cytosolic ATM in the DNA damage response. <i>Science Signaling</i> , <b>2011</b> , 4, pe2	8.8	48
42	Ubiquitin Conjugation and Deconjugation in NF-B Signaling. Sub-Cellular Biochemistry, 2010, 54, 88-99	5.5	8
41	A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains. <i>Journal of Immunology</i> , <b>2009</b> , 182, 7718-28	5.3	184
40	Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. <i>Journal of Experimental Medicine</i> , <b>2009</b> , 206, 2313-20	16.6	155
39	Role of oxidative stress in ultrafine particle-induced exacerbation of allergic lung inflammation. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 984-91	10.2	80
38	COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation. <i>EMBO Reports</i> , <b>2009</b> , 10, 642-8	6.5	27
37	The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the miRNA pathway protein Ago2. <i>Nature Cell Biology</i> , <b>2009</b> , 11, 1411-20	23.4	178
36	Inhibition of MALT1 Protease Activity Is Selectively Toxic for Activated B CellA ,A like Diffuse Large B Cell Lymphoma Cells <i>Blood</i> , <b>2009</b> , 114, 1271-1271	2.2	
35	Distinct isocomplexes of the TRAPP trafficking factor coexist inside human cells. <i>FEBS Letters</i> , <b>2008</b> , 582, 3729-33	3.8	21
34	MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit. <i>Nature Immunology</i> , <b>2007</b> , 8, 984-91	19.1	69

33	Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO Journal, 2007, 26, 4634	-4153	162
32	Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 1868-78	6.6	153
31	CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB. <i>Sciences STKE: Signal Transduction Knowledge Environment</i> , <b>2007</b> , 2007, pe21		53
30	Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation. <i>Molecular Cell</i> , <b>2006</b> , 23, 13-23	17.6	106
29	Controlling NF-kappaB activation in T cells by costimulatory receptors. <i>Cell Death and Differentiation</i> , <b>2006</b> , 13, 834-42	12.7	43
28	A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. <i>EMBO Reports</i> , <b>2005</b> , 6, 321-6	6.5	97
27	Viral targeting of the interferon-{beta}-inducing Traf family member-associated NF-{kappa}B activator (TANK)-binding kinase-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 13640-5	11.5	94
26	Degradation of Bcl10 induced by T-cell activation negatively regulates NF-kappa B signaling. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 3860-73	4.8	122
25	The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. <i>Molecular and Cellular Biology</i> , <b>2004</b> , 24, 6488-500	4.8	119
24	Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. <i>Oncogene</i> , <b>2004</b> , 23, 5378-86	9.2	186
23	Lymphotoxin and lipopolysaccharide induce NF-kappaB-p52 generation by a co-translational mechanism. <i>EMBO Reports</i> , <b>2003</b> , 4, 82-7	6.5	110
22	Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. <i>EMBO Journal</i> , <b>2002</b> , 21, 4104-13	13	270
21	Purification and characterization of the human elongator complex. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 3047-52	5.4	191
20	Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. <i>Journal of Experimental Medicine</i> , <b>2002</b> , 196, 605-17	16.6	218
19	Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. <i>Blood</i> , <b>2001</b> , 97, 2798-8	07.2	217
18	In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. <i>Leukemia</i> , <b>2001</b> , 15, 921-8	10.7	76
17	B-cell receptor- and phorbol ester-induced NF-kappaB and c-Jun N-terminal kinase activation in B cells requires novel protein kinase CTs. <i>Molecular and Cellular Biology</i> , <b>2001</b> , 21, 6640-50	4.8	71
16	Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha. <i>Molecular and Cellular Biology</i> , 2001 21 1024-35	4.8	124

## LIST OF PUBLICATIONS

15	Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. <i>American Journal of Human Genetics</i> , <b>2001</b> , 68, 598-605	11	477
14	NF-kappaB and the innate immune response. <i>Current Opinion in Immunology</i> , <b>2000</b> , 12, 52-8	7.8	305
13	Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. <i>Leukemia</i> , <b>2000</b> , 14, 399-402	10.7	233
12	The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 29779-87	5.4	99
11	Overexpression of I Kappa B Alpha Without Inhibition of NF- <b>B</b> Activity and Mutations in the I Kappa B Alpha Gene in Reed-Sternberg Cells. <i>Blood</i> , <b>1999</b> , 94, 3129-3134	2.2	230
10	NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. <i>Molecular and Cellular Biology</i> , <b>1999</b> , 19, 2690-8	4.8	683
9	Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. <i>Oncogene</i> , <b>1999</b> , 18, 943-53	9.2	241
8	NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. <i>EMBO Journal</i> , <b>1999</b> , 18, 4766-78	13	167
7	Overexpression of I Kappa B Alpha Without Inhibition of NF- <b>B</b> Activity and Mutations in the I Kappa B Alpha Gene in Reed-Sternberg Cells. <i>Blood</i> , <b>1999</b> , 94, 3129-3134	2.2	21
6	Signal-dependent degradation of IkappaBalpha is mediated by an inducible destruction box that can be transferred to NF-kappaB, bcl-3 or p53. <i>Nucleic Acids Research</i> , <b>1998</b> , 26, 1724-30	20.1	17
5	Regulation of NF-kappa B activity by I kappa B alpha and I kappa B beta stability. <i>Immunobiology</i> , <b>1997</b> , 198, 3-13	3.4	34
4	Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. <i>Journal of Clinical Investigation</i> , <b>1997</b> , 100, 2961-9	15.9	614
3	The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. Journal of Molecular Medicine, <b>1996</b> , 74, 749-69	5.5	213
2	Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo <i>EMBO Journal</i> , <b>1996</b> , 15, 6716-6726	13	157
1	High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. <i>Blood</i> , <b>1996</b> , 87, 4340-4347	2.2	286